Tag: CStone

CStone Submits Sugemalimab for Stage III Lung Cancer EMA Approval

March 24, 2025

CStone Pharmaceuticals, a biopharmaceutical company dedicated to developing innovative cancer therapies, announced the submission of a Type II variation application to the European Medicines Agency (EMA) for sugemalimab.

Encouraging Efficacy and Safety: CStone Presents Latest Clinical Data on CS5001 for Advanced Lymphoma at the 66th ASH Annual Meeting

December 9, 2024

HealthTech Insights: ESYA Labs Partners with Alamar Biosciences to Advance Biomarker Detection and Diagnostics for Neurological Diseases CStone Pharmaceuticals, an innovation-driven biopharmaceutical company focused on the

Categories

Tag: CStone

CStone Submits Sugemalimab for Stage III Lung Cancer EMA Approval

Encouraging Efficacy and Safety: CStone Presents Latest Clinical Data on CS5001 for Advanced Lymphoma at the 66th ASH Annual Meeting

Share With

Recent Posts

Tracer, QIAGEN Partner on Blood-Based MRD Test for Tumors

NextGen Healthcare Adds MDP as Investor, Plans Leadership Shift

JCR Pharma Launches Unique Global Site for 50th Anniversary

3 New Members Join Southern Nevada’s Top Regional Board

MedCore Opens New GI Surgery Center & Clinic in Arkansas

Quick Links

Insights

Get in touch

Follow Us

Our Other Brands